Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15322066 | 0.87 | PDE4A (0.31) | — | |
| Trifluoroacetic Acid SCHEMBL22718927 | 0.86 | HRH4 (0.31) | — | |
| SCHEMBL3378934 | 0.84 | PDE4A (0.33) | — | |
| SCHEMBL31673285 | 0.68 | — | — | |
| SCHEMBL23666181 | 0.66 | JAK2 (0.34) | — | |
| SCHEMBL25460799 | 0.64 | KDM4E (0.33) | — | |
| SCHEMBL30911176 | 0.61 | — | — | |
| SCHEMBL15326704 | 0.61 | — | — | |
| SCHEMBL8214992 | 0.61 | GRIN1 (0.32) | — | |
| SCHEMBL13831491 | 0.60 | OPRM1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3976027-B1 | QUINOLINE DERIVATIVES AS FACTOR XI ACTIVATION INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-11-05 | — | — | EP | disclosed |
| US-12304899-B2 | Factor XI activation inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-05-20 | — | — | US | disclosed |
| US-20220235033-A1 | FACTOR XI ACTIVATION INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2022-07-28 | — | — | US | disclosed |
| EP-3976027-A1 | FACTOR XI ACTIVATION INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2022-04-06 | — | — | EP | disclosed |
| WO-2020243049-A1 | FACTOR XI ACTIVATION INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12304899-B2 | Factor XI activation inhibitors | F11, TFPI, F13B | ALDH1A1 2315/4885HPGD 957/4885HSD17B10 1958/4885 |
| US-20220235033-A1 | FACTOR XI ACTIVATION INHIBITORS | F11, TFPI, F13B | ALDH1A1 2315/4885HPGD 957/4885HSD17B10 1958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.